260 related articles for article (PubMed ID: 33979196)
1. Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress.
Shields MD; Marin-Acevedo JA; Pellini B
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-23. PubMed ID: 33979196
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro ID; Califano R; Mountzios G; de Mello RA
Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
5. [Immune checkpoint inhibitors in lung cancer].
Koleczko S; Wolf J
Internist (Berl); 2020 Jul; 61(7):676-681. PubMed ID: 32462250
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
Decatris MP; O'Byrne KJ
Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
[TBL] [Abstract][Full Text] [Related]
9. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
[TBL] [Abstract][Full Text] [Related]
12. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
14. How I Treat Non-Small Cell Lung Cancer Refractory to Immunotherapy.
Wong SK; Horn L
Cancer J; 2020; 26(6):496-501. PubMed ID: 33298720
[TBL] [Abstract][Full Text] [Related]
15. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh S; Marabelle A; Soria JC; Armand JP
Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.
Shafique M; Tanvetyanon T
Expert Opin Biol Ther; 2019 Mar; 19(3):225-232. PubMed ID: 30657338
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
Qin A; Coffey DG; Warren EH; Ramnath N
Cancer Med; 2016 Sep; 5(9):2567-78. PubMed ID: 27416962
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Progress in the Immunotherapy of Small Cell Lung Cancer].
Wang W; Zhang J; Li S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):425-433. PubMed ID: 35747922
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
Marrone KA; Brahmer JR
Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]